Relay Therapeutics (RLAY) to Release Quarterly Earnings on Thursday

Relay Therapeutics (NASDAQ:RLAY - Get Free Report) is projected to release its Q1 2025 earnings data before the market opens on Thursday, May 1st. Analysts expect Relay Therapeutics to post earnings of ($0.51) per share and revenue of $0.01 million for the quarter.

Relay Therapeutics (NASDAQ:RLAY - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.45) EPS for the quarter, beating analysts' consensus estimates of ($0.57) by $0.12. On average, analysts expect Relay Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Relay Therapeutics Trading Down 0.2 %

Shares of RLAY traded down $0.01 during mid-day trading on Monday, reaching $3.20. The company's stock had a trading volume of 999,529 shares, compared to its average volume of 1,981,716. Relay Therapeutics has a 52 week low of $1.78 and a 52 week high of $10.72. The company's fifty day moving average price is $3.02 and its two-hundred day moving average price is $4.27. The stock has a market cap of $541.62 million, a PE ratio of -1.22 and a beta of 1.70.

Analyst Ratings Changes

A number of brokerages have commented on RLAY. Stifel Nicolaus decreased their price target on Relay Therapeutics from $27.00 to $23.00 and set a "buy" rating on the stock in a research note on Thursday, February 27th. Wells Fargo & Company assumed coverage on shares of Relay Therapeutics in a report on Thursday, April 17th. They set an "equal weight" rating and a $4.00 target price for the company. HC Wainwright reaffirmed a "buy" rating and set a $16.00 price target on shares of Relay Therapeutics in a research report on Friday, March 7th. Finally, The Goldman Sachs Group decreased their target price on Relay Therapeutics from $20.00 to $18.00 and set a "buy" rating for the company in a report on Thursday, February 27th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $18.36.

Insider Activity

In other Relay Therapeutics news, insider Peter Rahmer sold 17,250 shares of the business's stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $4.42, for a total transaction of $76,245.00. Following the completion of the sale, the insider now directly owns 402,431 shares in the company, valued at approximately $1,778,745.02. The trade was a 4.11 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Thomas Catinazzo sold 20,791 shares of the company's stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $4.42, for a total value of $91,896.22. Following the sale, the chief financial officer now owns 379,431 shares of the company's stock, valued at approximately $1,677,085.02. This trade represents a 5.19 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 357,840 shares of company stock valued at $1,358,217 in the last 90 days. 4.32% of the stock is currently owned by insiders.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.